|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Olema Pharmaceuticals, Inc. (OLMA) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
72,062,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for women's cancers. Co. is focused on developing therapies for the treatment of breast cancer. Co.'s wholly owned, primary product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist and a selective ER degrader. Co. is evaluating OP-1250 in a dose escalation and expansion trial for the treatment of ER-positive, human epidermal growth factor receptor 2-negative breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
300,000 |
1,000,761 |
| Total Buy Value |
$0 |
$0 |
$1,727,370 |
$6,457,507 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
1 |
2 |
| Total Shares Sold |
0 |
25,000 |
25,000 |
6,092,208 |
| Total Sell Value |
$0 |
$204,841 |
$204,841 |
$71,633,429 |
| Total People Sold |
0 |
1 |
1 |
7 |
| Total Sell Transactions |
0 |
4 |
4 |
33 |
| End Date |
2025-09-25 |
2025-06-24 |
2024-12-24 |
2023-12-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Zojwalla Naseem |
Chief Medical Officer |
• – – |
2025-12-23 |
4 |
S |
$27.66 |
$2,752,419 |
D/D |
(99,509) |
4,488 |
|
- |
|
| Zojwalla Naseem |
Chief Medical Officer |
• – – |
2025-12-23 |
4 |
OE |
$7.02 |
$351,000 |
D/D |
50,000 |
103,997 |
|
- |
|
| Zojwalla Naseem |
Chief Medical Officer |
• – – |
2025-12-22 |
4 |
S |
$28.04 |
$2,804,000 |
D/D |
(100,000) |
53,997 |
|
- |
|
| Zojwalla Naseem |
Chief Medical Officer |
• – – |
2025-12-22 |
4 |
OE |
$7.02 |
$703,392 |
D/D |
50,000 |
153,997 |
|
- |
|
| Myles David C. |
CH. DISCOV. & NON-CLIN DEV OFF |
• – – |
2025-12-19 |
4 |
GD |
$0.00 |
$0 |
D/D |
9,000 |
542,881 |
|
- |
|
| Myles David C. |
CH. DISCOV. & NON-CLIN DEV OFF |
• – – |
2025-12-19 |
4 |
S |
$28.08 |
$1,553,544 |
D/D |
(51,000) |
551,881 |
|
- |
|
| Clark Ian T |
|
– • – |
2025-12-19 |
4 |
S |
$28.83 |
$7,873,109 |
D/D |
(264,800) |
0 |
|
- |
|
| Clark Ian T |
|
– • – |
2025-12-19 |
4 |
OE |
$3.61 |
$1,219,544 |
D/D |
264,800 |
264,800 |
|
- |
|
| Zojwalla Naseem |
Chief Medical Officer |
• – – |
2025-12-19 |
4 |
S |
$28.03 |
$1,973,729 |
D/D |
(70,000) |
103,997 |
|
- |
|
| Zojwalla Naseem |
Chief Medical Officer |
• – – |
2025-12-19 |
4 |
OE |
$15.25 |
$610,000 |
D/D |
40,000 |
173,997 |
|
- |
|
| Kovacs Shane William Charles |
CH. OPERATING & FINANCIAL OFF. |
• – – |
2025-12-08 |
4 |
GD |
$0.00 |
$0 |
D/D |
75,000 |
243,549 |
|
- |
|
| Kovacs Shane William Charles |
CH. OPERATING & FINANCIAL OFF. |
• – – |
2025-11-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
225,000 |
318,549 |
|
- |
|
| Rappaport Andrew |
|
– • – |
2025-11-25 |
4 |
GD |
$0.00 |
$0 |
D/D |
35,868 |
0 |
|
- |
|
| Rappaport Andrew |
|
– • – |
2025-11-21 |
4 |
OE |
$0.39 |
$13,989 |
D/D |
35,868 |
35,868 |
|
- |
|
| Harmon Cyrus |
|
– • – |
2025-09-18 |
4 |
S |
$8.32 |
$25,676 |
I/I |
(3,086) |
117,028 |
|
- |
|
| Harmon Cyrus |
|
– • – |
2025-09-18 |
4 |
S |
$8.33 |
$83,300 |
D/D |
(10,000) |
744,140 |
|
- |
|
| Harmon Cyrus |
|
– • – |
2025-09-16 |
4 |
S |
$8.08 |
$15,465 |
I/I |
(1,914) |
120,114 |
|
- |
|
| Harmon Cyrus |
|
– • – |
2025-09-16 |
4 |
S |
$8.04 |
$80,400 |
D/D |
(10,000) |
754,140 |
|
- |
|
| Lampert Mark N |
See Explanation of Responses |
– • – |
2025-01-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(420,000) |
347,970 |
|
- |
|
| Bain Capital Life Sciences Opportunities Iv, L.p. |
|
– – • |
2025-01-10 |
4 |
D |
$0.00 |
$0 |
I/I |
(3,500,000) |
4,300,000 |
|
- |
|
| Bain Capital Life Sciences Opportunities Iv, L.p. |
|
– – • |
2025-01-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
7,500,000 |
|
- |
|
| Bain Capital Life Sciences Opportunities Iv, L.p. |
|
– – • |
2025-01-08 |
4 |
B |
$5.76 |
$1,727,370 |
I/I |
300,000 |
7,800,000 |
0.01 |
- |
|
| Graham G. Walmsley |
Director |
– • – |
2024-12-17 |
4 |
S |
$6.75 |
$4,730,137 |
I/I |
(700,761) |
1,408,875 |
|
- |
|
| Graham G. Walmsley |
Director |
– • – |
2024-12-17 |
4 |
S |
$6.75 |
$4,730,137 |
I/I |
(700,761) |
0 |
|
- |
|
| Zojwalla Naseem |
CHIEF MEDICAL OFFICER |
• – – |
2024-12-16 |
4 |
OE |
$4.87 |
$68,180 |
D/D |
14,000 |
129,509 |
|
- |
|
174 Records found
|
|
Page 1 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
